Cargando…
The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome
INTRODUCTION: Takotsubo syndrome (TTS) is clinically indistinguishable from an acute coronary syndrome (ACS). In the absence of valid markers for differential diagnosis, coronary angiography has been indispensable. METHODS: In our study, we evaluated the serum levels of sST-2, GDF-15, suPAR and H-FA...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816755/ https://www.ncbi.nlm.nih.gov/pubmed/34727211 http://dx.doi.org/10.1007/s00392-021-01956-2 |
_version_ | 1784645504267714560 |
---|---|
author | Topf, Albert Mirna, Moritz Paar, Vera Motloch, Lukas J. Grueninger, Janine Dienhart, Christiane Schulze, Paul C. Brandt, Mathias C. Larbig, Robert Hoppe, Uta C. Kretzschmar, Daniel Lichtenauer, Michael |
author_facet | Topf, Albert Mirna, Moritz Paar, Vera Motloch, Lukas J. Grueninger, Janine Dienhart, Christiane Schulze, Paul C. Brandt, Mathias C. Larbig, Robert Hoppe, Uta C. Kretzschmar, Daniel Lichtenauer, Michael |
author_sort | Topf, Albert |
collection | PubMed |
description | INTRODUCTION: Takotsubo syndrome (TTS) is clinically indistinguishable from an acute coronary syndrome (ACS). In the absence of valid markers for differential diagnosis, coronary angiography has been indispensable. METHODS: In our study, we evaluated the serum levels of sST-2, GDF-15, suPAR and H-FABP in 92 patients with the suspicion of TTS (51 TTS and 41 ACS patients) and 40 gender matched controls (no coronary artery disease or signs of heart failure) at baseline. RESULTS: H-FABP was significantly higher in ACS patients compared to TTS patients. Even in in propensity score matching for left ventricular ejection fraction, sex and cardiovascular risk factors, differences in the plasma levels of H-FABP in the matched cohort of TTS vs ACS remained statistically significant. Whereas, sST-2 was significantly elevated in TTS patients. H-FABP was superior for prediction of an ACS with even higher accuracy than hs troponin in differential diagnosis (AUC 0.797, p ≤ 0.0001); the optimal cut off for discrimination towards a TTS was calculated as 2.93 ng/ml (sensitivity 70.0%, specificity 82.4%, PPV 75.7%, NPV 77.4%). sST-2 seemed most appropriate for identification of a TTS (AUC 0.653, p = 0.012). The optimal cut off for differential diagnosis was 11018.06 pg/ml (sensitivity 82.0%, specificity 51.2%, PPV 69.4%, NPV 71.9 %). CONCLUSION: H-FABP and sST-2 are the most promising markers with better accuracy than preexisting biomarkers in differential diagnosis in our study and therefore, could be crucial for the guidance of treatment in patients with high bleeding risk, advanced renal failure or multimorbidity. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01956-2. |
format | Online Article Text |
id | pubmed-8816755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-88167552022-02-17 The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome Topf, Albert Mirna, Moritz Paar, Vera Motloch, Lukas J. Grueninger, Janine Dienhart, Christiane Schulze, Paul C. Brandt, Mathias C. Larbig, Robert Hoppe, Uta C. Kretzschmar, Daniel Lichtenauer, Michael Clin Res Cardiol Original Paper INTRODUCTION: Takotsubo syndrome (TTS) is clinically indistinguishable from an acute coronary syndrome (ACS). In the absence of valid markers for differential diagnosis, coronary angiography has been indispensable. METHODS: In our study, we evaluated the serum levels of sST-2, GDF-15, suPAR and H-FABP in 92 patients with the suspicion of TTS (51 TTS and 41 ACS patients) and 40 gender matched controls (no coronary artery disease or signs of heart failure) at baseline. RESULTS: H-FABP was significantly higher in ACS patients compared to TTS patients. Even in in propensity score matching for left ventricular ejection fraction, sex and cardiovascular risk factors, differences in the plasma levels of H-FABP in the matched cohort of TTS vs ACS remained statistically significant. Whereas, sST-2 was significantly elevated in TTS patients. H-FABP was superior for prediction of an ACS with even higher accuracy than hs troponin in differential diagnosis (AUC 0.797, p ≤ 0.0001); the optimal cut off for discrimination towards a TTS was calculated as 2.93 ng/ml (sensitivity 70.0%, specificity 82.4%, PPV 75.7%, NPV 77.4%). sST-2 seemed most appropriate for identification of a TTS (AUC 0.653, p = 0.012). The optimal cut off for differential diagnosis was 11018.06 pg/ml (sensitivity 82.0%, specificity 51.2%, PPV 69.4%, NPV 71.9 %). CONCLUSION: H-FABP and sST-2 are the most promising markers with better accuracy than preexisting biomarkers in differential diagnosis in our study and therefore, could be crucial for the guidance of treatment in patients with high bleeding risk, advanced renal failure or multimorbidity. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01956-2. Springer Berlin Heidelberg 2021-11-02 2022 /pmc/articles/PMC8816755/ /pubmed/34727211 http://dx.doi.org/10.1007/s00392-021-01956-2 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Topf, Albert Mirna, Moritz Paar, Vera Motloch, Lukas J. Grueninger, Janine Dienhart, Christiane Schulze, Paul C. Brandt, Mathias C. Larbig, Robert Hoppe, Uta C. Kretzschmar, Daniel Lichtenauer, Michael The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome |
title | The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome |
title_full | The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome |
title_fullStr | The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome |
title_full_unstemmed | The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome |
title_short | The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome |
title_sort | differential diagnostic value of selected cardiovascular biomarkers in takotsubo syndrome |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816755/ https://www.ncbi.nlm.nih.gov/pubmed/34727211 http://dx.doi.org/10.1007/s00392-021-01956-2 |
work_keys_str_mv | AT topfalbert thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT mirnamoritz thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT paarvera thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT motlochlukasj thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT grueningerjanine thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT dienhartchristiane thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT schulzepaulc thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT brandtmathiasc thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT larbigrobert thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT hoppeutac thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT kretzschmardaniel thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT lichtenauermichael thedifferentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT topfalbert differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT mirnamoritz differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT paarvera differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT motlochlukasj differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT grueningerjanine differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT dienhartchristiane differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT schulzepaulc differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT brandtmathiasc differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT larbigrobert differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT hoppeutac differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT kretzschmardaniel differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome AT lichtenauermichael differentialdiagnosticvalueofselectedcardiovascularbiomarkersintakotsubosyndrome |